TLDR: Glaucoma UK has allocated £240,000 in research grants to three innovative projects aimed at advancing glaucoma understanding, diagnosis, and treatment. A significant portion of the funding will support a project utilizing artificial intelligence to predict glaucoma progression patterns, alongside initiatives for regenerative implants and 3D optic nerve analysis.
Glaucoma UK, a leading charity dedicated to fighting sight loss from glaucoma, has announced the allocation of £240,000 in research grants for 2025, supporting three pivotal projects. These initiatives are set to push the boundaries of understanding and treating glaucoma, with a notable focus on leveraging advanced technologies, including artificial intelligence.
One of the key recipients is Associate Professor Kuang Hu from the UCL Institute of Ophthalmology, who secured a grant of nearly £90,000 for an 18-month project titled ‘Clarifying the Prognosis: Identifying Glaucoma Progression Patterns with Artificial Intelligence.’ This groundbreaking research will employ an AI tool known as SuStaIn to analyze optical coherence tomography (OCT) scans, aiming to identify distinct subtypes of glaucoma. This AI tool has previously demonstrated success in Alzheimer’s dementia research. Professor Hu emphasized the potential impact, stating, ‘This research will help pinpoint people at higher risk of vision loss from glaucoma, allowing for closer monitoring and earlier treatment, while also providing reassurance to those at lower risk and making the best use of NHS resources. Receiving this grant is a tremendous privilege, as it not only supports our work but also endorses its importance through the backing of expert patients and professionals at Glaucoma UK.’
Another substantial grant, just under £100,000, was awarded to Dr. Lucy Bosworth and her team at the University of Liverpool. Their year-long project, ‘LIVTM: A Regenerative Cell-Based Implant to Restore Natural Eye Drainage in Glaucoma,’ focuses on developing a bioengineered scaffold. This implant is designed to be placed into the trabecular meshwork drainage channels of the eye, with the dual aim of improving fluid drainage and restoring the health of the meshwork. Dr. Bosworth expressed optimism about the long-term benefits, remarking, ‘Our hope is that this work will contribute to long-term treatments that protect vision and improve quality of life for people living with glaucoma.’
Finally, Dr. Colin Chu and his collaborators from the UCL Institute of Ophthalmology received a grant of close to £50,000 for their year-long project, ‘Characterizing the 3D Spatial Biology of the Human Optic Nerve Head in Glaucoma.’ This research will utilize cutting-edge technology to conduct 3D studies of changes in donor eyes, providing unprecedented insights into the intricate interactions of cells supporting the optic nerve and how they are affected by the disease. Dr. Chu noted, ‘This grant allows us to start a collaboration, to apply cutting-edge technologies to study changes in donor eyes from patients that had glaucoma. We hope it will give us new insights, as we will be able to look in 3D at all the different interacting cells that support the optic nerve and how they alter in disease.’
Also Read:
- Artificial Intelligence Revolutionizes Clinical Trials in India
- Europe Intensifies Generative AI Development with GenAI4EU Initiative
These grants underscore Glaucoma UK’s commitment to funding innovative research that promises to significantly improve the lives of individuals affected by glaucoma, from early diagnosis and personalized treatment to regenerative therapies.
